Edition:
India

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

72.39USD
27 Jun 2017
Change (% chg)

$-0.35 (-0.48%)
Prev Close
$72.74
Open
$72.70
Day's High
$73.06
Day's Low
$72.25
Volume
1,747,669
Avg. Vol
1,858,704
52-wk High
$73.67
52-wk Low
$55.10

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Overall

Beta: 1.52
Market Cap(Mil.): $115,211.60
Shares Outstanding(Mil.): 1,591.54
Dividend: 0.64
Yield (%): 3.54

Financials

  ABBV.N Industry Sector
P/E (TTM): 18.64 13.69 17.46
EPS (TTM): 3.88 -- --
ROI: 12.64 -6.93 -5.20
ROE: 130.90 -6.40 -4.44

BRIEF-EU medicines agency recommends approval of Aveo's kidney cancer drug

* EU Medicines Agency recommends approval of Merck KGAA multiple sclerosis drug

23 Jun 2017

BRIEF-Enanta announces that AbbVie receives CHMP positive opinion for MAVIRET

* Enanta announces that abbvie receives chmp positive opinion for maviret™ (glecaprevir/pibrentasvir) for the treatment of chronic hepatitis c in all major genotypes (gt1-6)

23 Jun 2017

BRIEF-EMA recommends approval of Merck's multiple sclerosis drug

* EU Medicines Agency recommends approval of Merck KGAA multiple sclerosis drug

23 Jun 2017

BRIEF-AbbVie sets quarterly cash dividend of $0.64 per share

* Abbvie Inc says declared a quarterly cash dividend of $0.64 per share Source text for Eikon: Further company coverage:

23 Jun 2017

Business lobby claims RICO charges against pharma will chill free speech

It’s always revealing to track amicus filings by groups like the U.S. Chamber of Commerce, the National Association of Manufacturers and the Washington Legal Foundation. I regard amicus briefs from the business lobby as a rough index of litigation threats to U.S. companies - or, at least, an indicator of what companies perceive to be litigation threats. Based on that assumption, it looks like businesses, and, in particular, pharmaceutical companies, are still worried about the prospe

14 Jun 2017

BRIEF-AbbVie and Principia to collaborate on oral immunoproteasome inhibitors

* AbbVie and Principia announce collaboration on oral immunoproteasome inhibitors

13 Jun 2017

AbbVie must pay $15 million in Depakote birth-defect trial: jury

A federal jury on Friday awarded $15 million to a 10-year-old boy whose mother blamed his birth defect on AbbVie Inc's bipolar disorder drug Depakote that she took while pregnant, in the latest trial among hundreds of lawsuits over the product.

10 Jun 2017

UPDATE 2-AbbVie must pay $15 mln in Depakote birth-defect trial: jury

June 9 A federal jury on Friday awarded $15 million to a 10-year-old boy whose mother blamed his birth defect on AbbVie Inc's bipolar disorder drug Depakote that she took while pregnant, in the latest trial among hundreds of lawsuits over the product.

10 Jun 2017

AbbVie suffers $15 million loss in Depakote birth-defect trial

June 9 A federal jury on Friday awarded $15 million to a California woman who blamed her son's birth defects on AbbVie Inc's bipolar disorder drug Depakote, in the latest trial to spill out of hundreds of lawsuits over the drug.

09 Jun 2017

AbbVie's rheumatoid arthritis drug succeeds in trial

AbbVie Inc said on Wednesday its oral rheumatoid arthritis drug succeeded in a late-stage study on patients who had not adequately responded to standard treatments.

08 Jun 2017

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $135.01 -1.33
Pfizer Inc. (PFE.N) $33.77 -0.27
Novartis AG (NOVN.S) CHF82.15 -0.65
Merck & Co., Inc. (MRK.N) $65.54 -0.38
Roche Holding Ltd. (ROG.S) CHF250.80 -1.20
Roche Holding Ltd. (RO.S) CHF253.25 -1.75
Abbott Laboratories (ABT.N) $48.67 -0.24
Eli Lilly and Co (LLY.N) $83.04 -1.24
Sanofi SA (SASY.PA) €86.54 -1.09

Earnings vs. Estimates